Hisense Debuts 116″ UX TV with RGB-MiniLED for Stunning Color Precision
QINGDAO, China, July 9, 2025 /PRNewswire/ -- Hisense, a leading brand in…
IOC President Coventry announces two working groups to strengthen future host election process and protection of the female category
26 June 2025 - Following a “Pause and Reflect” workshop with International Olympic…
FAIR PLAY MENARINI INTERNATIONAL AWARD, A WAVE OF EMOTIONS MARKS THE 29TH EDITION
FIESOLE, Italy, July 4, 2025 /PRNewswire/ -- A night suspended between history…
Abu Dhabi Celebrates its Starring Role in F1: The Movie at Yas Marina Circuit
ABU DHABI, UAE, July 3, 2025 /PRNewswire/ -- Following the regional premiere of…
Redefining the Future of Sports: Xtep and Unitree Technology Showcase China’s New Speed in Running and Technology
XIAMEN, China--(BUSINESS WIRE)--On June 29, 2025, the Running at the Castle of…
Award-Winning Self-Service Registration: DERMALOG Sets New Standards for Security and Efficiency
The German Design Council has once again honored outstanding innovations in Berlin.…
ECLT10 Season 3 Auction Shatters Records with Historic Bids and Power-Packed Rosters
NEW DELHI, June 16, 2025 /PRNewswire/ -- The ECLT10 Season 3 Auction,…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
- The Company is developing an enhanced immunosuppressive regimen in consultation with…
Chromafora Receives Frost & Sullivan’s 2025 Global New Product Innovation Award for Excellence in PFAS Water Treatment Solutions
Recognized for its proprietary SELPAXT™ technology, Chromafora is setting a new standard…